Ivan Hyep sold $341k of BCAX
Chief Financial Officer at Bicara Therapeutics Inc.. 18,400 shares at an average of $18.54, traded Nov 21, 2025, filed Nov 25, 2025.
Score components
- +22RoleCFO
- +15Trade size$341k at market
- +5Share of holdings soldSold 13% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0002034668-25-000010, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 21, 2025 | MOption exercise Common Stock10b5-1 | +605 | $3.79 | $2,293 | 145,960 | Nov 25, 2025 |
| Nov 21, 2025 | SOpen-market sale Common Stock10b5-1 | -605 | $18.15 | $11k | 145,355 | Nov 25, 2025 |
| Nov 24, 2025 | MOption exercise Common Stock10b5-1 | +17,795 | $3.79 | $67k | 163,150 | Nov 25, 2025 |
| Nov 24, 2025 | SOpen-market sale Common Stock10b5-1 | -17,795 | $18.55 | $330k | 145,355 | Nov 25, 2025 |
| Nov 21, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -605 | $0.00 | $0 | 115,979 | Nov 25, 2025 |
| Nov 24, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -17,795 | $0.00 | $0 | 98,184 | Nov 25, 2025 |
Related signals
Other insiders at Bicara Therapeutics Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 6Weak | Bicara Therapeutics Inc. | Ryan Cohlhepp President, COO & Interim CEO | $401k 17,500 shares | -9% | |
| 5Weak | Bicara Therapeutics Inc. | David Raben Chief Medical Officer | $104k 5,500 shares | -9% | |
| 13Weak | Bicara Therapeutics Inc. | Ivan Hyep Chief Financial Officer | $170k 9,200 shares | -6% | |
| 19Weak | Bicara Therapeutics Inc. | Claire Mazumdar Chief Executive Officer | $282k 15,000 shares | -4% | |
| 13Weak | Bicara Therapeutics Inc. | Ryan Cohlhepp President and COO | $246k 12,500 shares | -6% | |
| 26Weak | Bicara Therapeutics Inc. | Claire Mazumdar Chief Executive Officer | $705k 36,766 shares | -10% | |
| 16Weak | Bicara Therapeutics Inc. | Claire Mazumdar Chief Executive Officer | $154k 8,234 shares | -2% | |
| 19Weak | Bicara Therapeutics Inc. | David Raben Chief Medical Officer | $306k 16,500 shares | -30% | |
| 21Weak | Bicara Therapeutics Inc. | Ivan Hyep Chief Financial Officer | $301k 16,518 shares | -10% | |
| 14Weak | Bicara Therapeutics Inc. | Ryan Cohlhepp President and COO | $316k 17,392 shares | -8% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.